News
PHMMF
105.60
NaN%
--
Pharma Mar SA Reports on Recent Share Buy-Back Activities
TipRanks · 3d ago
Weekly Report: what happened at PHMMF last week (0414-0418)?
Weekly Report · 4d ago
Weekly Report: what happened at PHMMF last week (0407-0411)?
Weekly Report · 04/14 09:36
Weekly Report: what happened at PHMMF last week (0331-0404)?
Weekly Report · 04/07 09:35
Pharma Mar Adjusts Financial Strategy with New Share Buyback Program
TipRanks · 04/04 10:04
Pharma Mar’s Credit Rating Maintained at ‘BB+’
TipRanks · 04/04 07:32
Pharma Mar Partners with Merck for Japanese Launch of Cancer Drug
TipRanks · 04/03 07:01
Pharma Mar Implements Share Delivery Plan to Boost Employee Engagement
TipRanks · 04/02 20:39
Weekly Report: what happened at PHMMF last week (0324-0328)?
Weekly Report · 03/31 09:38
Sylentis Secures 21.1 Million Euro Grant for RNA Drug Production
TipRanks · 03/27 12:07
PharmaMar Proposes 23% Dividend Increase Amid Strong Financial Performance
TipRanks · 03/26 08:02
Weekly Report: what happened at PHMMF last week (0317-0321)?
Weekly Report · 03/24 09:35
Weekly Report: what happened at PHMMF last week (0310-0314)?
Weekly Report · 03/17 09:38
Weekly Report: what happened at PHMMF last week (0303-0307)?
Weekly Report · 03/10 09:39
Needham Reaffirms Their Buy Rating on Pharma Mar SA (PHMMF)
TipRanks · 03/03 11:56
Weekly Report: what happened at PHMMF last week (0224-0228)?
Weekly Report · 03/03 09:39
Pharma Mar SA Reports Strong 2024 Financial Results
TipRanks · 03/01 04:14
Pharma Mar Releases 2024 Director Remuneration Report
TipRanks · 02/28 09:45
PharmaMar SA Reports Strong Financial Growth in 2024
TipRanks · 02/28 08:21
Pharma Mar S.A. Initiates Share Buy-back Program to Enhance Shareholder Value
TipRanks · 02/28 08:19
More
Webull provides a variety of real-time PHMMF stock news. You can receive the latest news about Pharma Mar Sa through multiple platforms. This information may help you make smarter investment decisions.
About PHMMF
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.